Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

MLA

Sandrine Faivre, et al. “Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival from a Phase III Randomized Study.” Annals of Oncology, vol. 28, Feb. 2017, pp. 339–43. EBSCOhost, https://doi.org/10.1093/annonc/mdw561.

APA

Sandrine Faivre, Patricia Niccoli, Aaron I. Vinik, Peter Metrakos, C. Lombard-Bohas, D. Smith, Y.-J. Bang, K.J. Ishak, Pascal Hammel, Shem Patyna, Jean-Luc Raoul, E. Raymond, Jin-Shyr Chen, E. Van Cutsem, Ivan Borbath, Daniel Castellano, D. Lu, Juan W. Valle, J.F. Seitz, … Sang Hyub Lee. (2017). Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of Oncology, 28, 339–343. https://doi.org/10.1093/annonc/mdw561

Chicago

Sandrine Faivre, Patricia Niccoli, Aaron I. Vinik, Peter Metrakos, C. Lombard-Bohas, D. Smith, Y.-J. Bang, et al. 2017. “Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival from a Phase III Randomized Study.” Annals of Oncology 28 (February): 339–43. doi:10.1093/annonc/mdw561.